SCHEMBL1494518

SCHEMBL1494518

CCCOc1[c]nccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 1/20 0.38
TLR8 Q9NR97 1/20 0.36
GRM5 P41594 1/20 0.34
CHRNB2 P17787 2/20 0.33
CHRNA4 P43681 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494205 0.91 CYP2D6 (0.42) NPC1RAB9AMAPTSMN1; SMN2TLR8
SCHEMBL1494545 0.89 LTA4H (0.40) NPC1MAPTSMN1; SMN2MAPK1TLR8
SCHEMBL1494289 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1494281 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1494604 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1494434 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1494520 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1494447 0.87 LMNA (0.40) NPC1MAPTSMN1; SMN2TLR8CYP3A4
SCHEMBL1036211 0.84
SCHEMBL2066473 0.83 TSHR (0.38) NPC1RAB9ASMN1; SMN2CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206886-A Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same 广东聚华印刷显示技术有限公司 2022-03-18 CN claimed
WO-2021016814-A1 LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-02-04 WO claimed
CN-102781942-A Disubstituted octahy-dropyrrolo [3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV 2012-11-14 CN claimed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP claimed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO claimed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US claimed
CN-114206886-A Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same 广东聚华印刷显示技术有限公司 2022-03-18 CN disclosed
US-20210115058-A1 SPIROCYCLIC COMPOUNDS RECURIUM IP HOLDINGS, LLC 2021-04-22 US disclosed
US-10934304-B2 Spirocyclic compounds RECURIUM IP HOLDINGS, LLC (US) 2021-03-02 US disclosed
WO-2021016814-A1 LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-02-04 WO disclosed
US-20200207776-A1 SPIROCYCLIC COMPOUNDS Zeno Royalties & Milestones, LLC 2020-07-02 US disclosed
EP-3523306-A1 SPIROCYCLIC COMPOUNDS Zeno Royalties & Milestones, LLC (US) 2019-08-14 EP disclosed
US-10190009-B2 Ink composition, ink jet recording method using same, and colored material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-7179922-B2 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders ASTRAZENECA AB (SE) 2007-02-20 US disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
US-20050171092-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2005-08-04 US disclosed
US-6903115-B2 Bipiperidine compounds ASTRAZENECA AB (SE) 2005-06-07 US disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 US disclosed
WO-2002043680-A1 FIXATION OF CARBOHYDRATES TO FIBROUS MATERIALS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2002-06-06 WO disclosed
WO-2002043678-A2 ENZYMATIC FIXATION OF DERIVATISED CARBOHYDRATES TO FIBROUS MATERIALS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115058-A1 SPIROCYCLIC COMPOUNDS PKD1, AR, PKD2 NPC1 32/4885RAB9A 1456/4885MAPT 4238/4885
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 NPC1 388/4885RAB9A 646/4885MAPT 1605/4885
US-20050171092-A1 Chemical compounds CCR3, CCR1, CCR4 NPC1 887/4885RAB9A 2189/4885MAPT 2117/4885
US-20200207776-A1 SPIROCYCLIC COMPOUNDS PKD1, AR, PKD2 NPC1 32/4885RAB9A 1456/4885MAPT 4238/4885
US-10934304-B2 Spirocyclic compounds PKD1, AR, PKD2 NPC1 32/4885RAB9A 1456/4885MAPT 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.